Octagon Capital Advisors’s Avidity Biosciences RNAM Stock Holding History

Octagon Capital Advisors’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-382,000	Closed	-$5.86M	–	45
2023 Q1	$5.86M	Buy	382,000 +57,371	+18%	+$1.26M	0.84%	23
2022 Q4	$7.2M	Sell	324,629 -55,000	-14%	-$820K	1.12%	19
2022 Q3	$6.2M	Buy	379,629 +57,988	+18%	+$1.11M	1.07%	22
2022 Q2	$4.67M	Hold	321,641	–	–	1.25%	12
2022 Q1	$5.94M	Sell	321,641 -125,000	-28%	-$2.12M	1.28%	18
2021 Q4	$10.6M	Hold	446,641	–	–	2.07%	14
2021 Q3	$11M	Hold	446,641	–	–	2.71%	12
2021 Q2	$11M	Hold	446,641	–	–	2.29%	15
2021 Q1	$9.74M	Buy	446,641 +16,600	+4%	+$406K	3.67%	11
2020 Q4	$11M	Buy	+430,041	New	+$12.5M	3.8%	12

Other funds holding RNAM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Octagon Capital Advisors's RNAM Position: Q2 2023 in Review

Octagon Capital Advisors sold out of Avidity Biosciences (RNAM) in Q2 2023, closing a stake of 382,000 shares — an estimated $5.86M sold.

Octagon Capital Advisors first reported a position in RNAM in Q4 2020 and held it in 10 quarters. The position peaked at $11M in Q2 2021. 143 funds tracked by Wall St. Rank hold RNAM as of Q2 2023.

Octagon Capital Advisors reported no remaining Avidity Biosciences position as of Q2 2023 after selling out during the quarter.
Octagon Capital Advisors sold 382,000 Avidity Biosciences shares in Q2 2023, an estimated $5.86M.
Octagon Capital Advisors first reported a position in Avidity Biosciences in Q4 2020 and held it in 10 quarters.
Octagon Capital Advisors's Avidity Biosciences position peaked at $11M in Q2 2021.
143 funds tracked by Wall St. Rank held Avidity Biosciences as of Q2 2023.

Based on Octagon Capital Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.